Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
CRI-CCTG-002
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
- NCT04093167 ↗
- Active, not recruiting
- Canadian Cancer Trials Group
- Deep
We haven't built an HCP commentary report on CRI-CCTG-002 (pembrolizumab in Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CRI-CCTG-002 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 21 | |
| Podcasts | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Cancer
- Interventions
- Pembrolizumab
- Arms
- Pembrolizumab alone · Active comparator
- Pembrolizumab + standard platinum-based chemotherapy · Experimental
- Enrollment
- 53
- Primary outcomes
- Stage 1: Concordance rate between molecular response and radiologic response
- Stage 2: Phase II Progression-Free Survival (PFS)
- Stage 2: Phase III Overall Survival
- Sponsor
- Canadian Cancer Trials Group with Cancer Research Institute, New York City, Personal Genome Diagnostics, Mark Foundation for Cancer Research
- Start
- May 26, 2020
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04093167 · updated Jul 31, 2026
Publications
linked from the registry- Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023 Oct;29(10):2559-2569. doi: 10.1038/s41591-023-02598-9. Epub 2023 Oct 9. PubMed 37814061